{"schema_version":"secwatch.filing_event.v1","accession":"0001816590-22-000117","form_type":"8-K","ticker":"CMPS","cik":"0001816590","company_name":"COMPASS Pathways plc","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.280676+00:00","generated_at":"2026-06-22T09:46:05.079724+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"COMPASS Pathways: Q3 net loss $18.4M ($0.43/share); Phase 3 program on track for 2022 start","bullets":["Net loss of $18.4M in Q3 2022 vs. $15.8M in Q3 2021; cash $173.1M as of Sept 30, 2022.","Phase 3 pivotal program for COMP360 in treatment-resistant depression on track to start in 2022.","Phase 2b trial data published in The New England Journal of Medicine.","Phase 2 trials ongoing in anorexia nervosa and PTSD; investigator-led study in autism launched."],"urls":{"canonical":"https://secwatch.observer/filing/0001816590-22-000117","json":"https://secwatch.observer/filing/0001816590-22-000117.json","markdown":"https://secwatch.observer/filing/0001816590-22-000117.md","text":"https://secwatch.observer/filing/0001816590-22-000117.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816590/000181659022000117/0001816590-22-000117-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816590/000181659022000117/cmps-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T09:46:05.079724+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c116f6a3af4d4e6c2a4d77d61e294a02a42c19cf","claim":"COMPASS Pathways plc reported three months and nine months ended September 30, 2022 results: net income Net loss for the three months ended 30 September 2022 was $18.4 million, or $0.43 loss per share, EPS $0.43 loss per share.","evidence_excerpt":"Net loss for the three months ended 30 September 2022 was $18.4 million, or $0.43 loss per share (including non-cash share-based compensation expense of $3.5 million), compared with $15.8 million or $0.38 loss per share, during the same period in 2021","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1816590/000181659022000117/0001816590-22-000117-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months and nine months ended September 30, 2022"},{"label":"Net income","value":"Net loss for the three months ended 30 September 2022 was $18.4 million, or $0.43 loss per share"},{"label":"EPS","value":"$0.43 loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}